Use of dupilumab in a patient with atopic dermatitis, severe asthma, and HIV infection
2020; Wiley; Volume: 33; Issue: 6 Linguagem: Inglês
10.1111/dth.14159
ISSN1529-8019
AutoresPetra Brodská, Petr Panzner, Dalibor Sedláček, Milan Teřl, Petra Cetkovská,
Tópico(s)Urticaria and Related Conditions
ResumoDupilumab is a monoclonal antibody against interleukin 4 (IL-4) receptor α that blocks signaling from IL-4 and IL-13, essential mediators of T helper 2 (Th2) pathway. To date, all clinical trials investigating the use of dupilumab excluded patients with human immunodeficiency virus. Herein, we describe the safe and successful use of dupilumab in a patient with atopic dermatitis, severe therapy resistant asthma, and HIV infection.
Referência(s)